[go: up one dir, main page]

PE20050086A1 - PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT AND SODIUM BICARBONATE - Google Patents

PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT AND SODIUM BICARBONATE

Info

Publication number
PE20050086A1
PE20050086A1 PE2004000356A PE2004000356A PE20050086A1 PE 20050086 A1 PE20050086 A1 PE 20050086A1 PE 2004000356 A PE2004000356 A PE 2004000356A PE 2004000356 A PE2004000356 A PE 2004000356A PE 20050086 A1 PE20050086 A1 PE 20050086A1
Authority
PE
Peru
Prior art keywords
pharmaceutically acceptable
sodium bicarbonate
combination including
acceptable salt
pharmaceutical combination
Prior art date
Application number
PE2004000356A
Other languages
Spanish (es)
Inventor
Michael John Humphrey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20050086A1 publication Critical patent/PE20050086A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMBINACION QUE COMPRENDE: (a) ELETRIPTAN, 3-{[1-METIL-PIRROLIDIN-2-(R)-IL]METIL}-5-(2-FENILSULFONIL-ETIL)-1H-INDOL, O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES, Y (b) BICARBONATO DE SODIO PARA SU USO EN EL TRATAMIENTO O LA PREVENCION DE UNA ENFERMEDAD PARA LA QUE ES INDICADO UN AGENTE AGONISTA DE 5-HT1, PARTICULARMENTE PARA SU USO EN EL TRATAMIENTO DE UNA MIGRANA O EN LA PREVENCION DE UNA RECURRENCIA DE MIGRANA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA ADAPTADA PARA LA ADMINISTRACION POR VIA ORAL EN FORMA DE TABLETA O EN FORMA DE UNA COMPOSICION NO EFERVESCENTEREFERS TO A COMBINATION INCLUDING: (a) ELETRIPTAN, 3 - {[1-METHYL-PYRROLIDIN-2- (R) -IL] METHYL} -5- (2-PHENYLSULFONYL-ETHYL) -1H-INDOLE, OR A OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS, AND (b) SODIUM BICARBONATE FOR USE IN THE TREATMENT OR PREVENTION OF A DISEASE FOR WHICH A 5-HT1 AGONIST AGENT IS INDICATED, PARTICULARLY FOR USE IN THE TREATMENT OF A MIGRAN OR THE PREVENTION OF A MIGRANE RECURRENCE. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION ADAPTED FOR ADMINISTRATION BY THE ORAL ROUTE IN TABLET FORM OR IN THE FORM OF A NON-EFFERVESCENT COMPOSITION

PE2004000356A 2003-04-11 2004-04-07 PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT AND SODIUM BICARBONATE PE20050086A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
PE20050086A1 true PE20050086A1 (en) 2005-03-01

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000356A PE20050086A1 (en) 2003-04-11 2004-04-07 PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT AND SODIUM BICARBONATE

Country Status (12)

Country Link
EP (1) EP1615635A1 (en)
JP (1) JP2006522790A (en)
AR (1) AR044009A1 (en)
BR (1) BRPI0409127A (en)
CA (1) CA2521902A1 (en)
MX (1) MXPA05010070A (en)
NL (1) NL1025908C2 (en)
PA (1) PA8599901A1 (en)
PE (1) PE20050086A1 (en)
TW (1) TW200423929A (en)
UY (1) UY28260A1 (en)
WO (1) WO2004089365A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
IT1393700B1 (en) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint SYNTHESIS OF 3 - {[(2R) -1-METHYLPYROLIDIN-2-IL] METHYL} -5- [2- (PHENILSULFONYL) ETYL] -1H-INDOL
JP6878021B2 (en) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 Pharmaceutical composition containing triptan and ascorbic acid
MX2020014128A (en) * 2018-07-03 2021-06-18 Axsome Therapeutics Inc PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM.
NZ778435A (en) * 2019-02-06 2024-12-20 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (en) * 1986-08-01 1988-11-25 Zambon Spa PHARMACEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (en) * 1993-03-26 1997-06-11 Zambon Spa PHARMECEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
CO5261541A1 (en) * 1999-05-14 2003-03-31 Pfizer Prod Inc COMBINATION THERAPY FOR THE TREATMENT OF MIGRANA
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
AU2004212976A1 (en) * 2003-02-19 2004-09-02 Biovail Laboratories Inc. Rapid absorption selective 5-HT agonist formulations

Also Published As

Publication number Publication date
JP2006522790A (en) 2006-10-05
CA2521902A1 (en) 2004-10-21
PA8599901A1 (en) 2005-02-04
TW200423929A (en) 2004-11-16
EP1615635A1 (en) 2006-01-18
AR044009A1 (en) 2005-08-24
UY28260A1 (en) 2004-11-30
BRPI0409127A (en) 2006-03-28
NL1025908C2 (en) 2005-11-22
MXPA05010070A (en) 2005-11-23
WO2004089365A1 (en) 2004-10-21
NL1025908A1 (en) 2004-10-13

Similar Documents

Publication Publication Date Title
AR110010A2 (en) PHARMACEUTICAL COMPOSITION FORMULATED IN A SINGLE DOSE FORM OF 2- [6- (3-AMINO-PIPERIDIN-1-IL) -3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-ILLAMBLE ] -4-FLUORO-BENZONITRILO
CL2004000643A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A 5-HT 1B / 1D AGONIST AND A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR, USEFUL IN THE TREATMENT OF MIGRANE.
MA29799B1 (en) ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS
CO5070571A1 (en) PHARMACEUTICAL MOXIFLOXACINE PREPARATION
ES2255287T3 (en) COMPOSITIONS FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA.
EP1575566A4 (en) MULTILAYER GALENIC FORMS CONTAINING NSAIDS AND TRIPTANES
ATE350040T1 (en) STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING A NON-STEROID ANTI-INFLAMMATORY ACT AND PROSTAGLANDIN
PT833618E (en) PHARMACEUTICAL FORM SOLID FOR ORAL USE
PE20030347A1 (en) PHARMACEUTICAL COMPOSITIONS, KITS AND PROCEDURES INVOLVING COMBINATIONS OF AGONISTS / ANTAGONISTS OF ESTROGEN, ESTROGEN AND PROGESTINES
RU2016122609A (en) COMPOSITIONS OF AZAINDOL COMPOUNDS
ES2176106A1 (en) Matrix tablet for sustained release of trimetazidine after oral administration
AR074793A1 (en) LIQUID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE TRIPTAN AND XYLITOL TO TREAT MIGRANE
AR031679A1 (en) A PHARMACEUTICAL COMPOSITION
GT200100149A (en) COMPOSITION OF ELETRIPTAN IN THE FORM OF PARTICLES.
PE20050086A1 (en) PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT AND SODIUM BICARBONATE
BR9912588A (en) Preventing migraine recurrence
AR022621A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DEOXIPEGANINE FOR THE TREATMENT OF NICOTINE DEPENDENCE
CO5611148A2 (en) PHARMACEUTICAL COMPOSITIONS OF A PDE4 OR PDE3 / 4 INHIBITOR AND A HISTAMINE RECEIVER ANTAGONIST
AR035406A1 (en) ELETRIPTAN PREPARATION PROCEDURE
AR033807A1 (en) USE OF (R) - (-) - 2- [5- (4-FLUOROPHENYL) -3-PIRIDYLMETHYLAMINOME] -CROMANO AND ITS ACCEPTABLE SALTS FOR PHYSIOLOGICAL USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
PA8606001A1 (en) SAQUINAVIR MESILATO, ORAL DOSAGE FORM
HUP0400495A2 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
PE20010123A1 (en) 5HT1 RECEPTOR AGONISTS AND A COX-2 INHIBITOR OR AN NSAID FOR THE TREATMENT OF MIGRANA
DOP2004000871A (en) PHARMACEUTICAL COMBINATION
CL2004000751A1 (en) PHARMACEUTICAL COMBINATION CONTAINING (A) ELETRIPAN, OR ONE OF ITS SALTS, AND (B) SODIUM BICARBONATE; COMPOSITION AND PHARMACEUTICAL PRODUCT CONTAINING SUCH COMBINATION; AND ITS USE IN THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR TREATMENT AND PREV

Legal Events

Date Code Title Description
FD Application declared void or lapsed